A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

NCT07014540 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinomas (NEC)

Interventions

DRUG: Irinotecan Hydrochloride Liposome Injection
DRUG: 5-FU
DRUG: LV

Sponsor

Beijing GoBroad Hospital

Collaborators

[object Object]